Jaime R. Merchan

Also affiliated with Sylvester Comprehensive Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets”.

Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets

Nature Reviews Urology(2022)10.1038/s41585-022-00654-6

N/A

0DataRank · unranked

173 citations

Helen Y. Hougen, Jaime R. Merchan, Mark L. Gonzalgo, Scott M. Welford, Sze Kiat Tan

Cellular and molecular effects of PNCK, a non-canonical kinase target in renal cell carcinoma

iScience(2022)10.1016/j.isci.2022.105621

N/A

0DataRank · unranked

2 citations

Valery Chávez, Floritza Bustamante, Stephan C. Schürer, Jaime R. Merchan, Derek J. Essegian

AI-Assisted Chemical Probe Discovery for the Understudied Calcium-Calmodulin Dependent Kinase, PNCK

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.06.01.494277

N/A

0DataRank · unranked

1 citations

Valery Chávez, Rabia Khurshid, Jaime R. Merchan, Stephan C. Schürer, Derek J. Essegian

Cellular And Molecular Effects Of Understudied Kinase Pregnancy-Upregulated Non-Ubiquitous Calcium-Calmodulin Dependent Kinase (PNCK) In Renal Cell Carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.05.09.491212

N/A

0DataRank · unranked

0 citations

Valery Chávez, Floritza Bustamante, Stephan C. Schürer, Jaime R. Merchan, Derek J. Essegian

AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK

PLoS Computational Biology(2023)10.1371/journal.pcbi.1010263

N/A

0DataRank · unranked

4 citations

Valery Chávez, Rabia Khurshid, Jaime R. Merchan, Stephan C. Schürer, Derek J. Essegian

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4505

N/A

0DataRank · unranked

21 citations

Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes +14 more

A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects

Molecular Therapy(2025)10.1016/j.ymthe.2025.08.027

N/A

0DataRank · unranked

2 citations

Jordi Rodon, Shree Venkat, Arthur Donahue, Amber Thomassen, William P. Accomando +10 more